Healthcare Nov 18, 2021 09:22 AM (GMT+8) · EqualOcean
Yiouda health learned on the 18th that Shanghai Lingtai Biomedical Technology Co., Ltd. (hereinafter referred to as Lingtai Biology) announced the completion of the pre-A round of financing, which was led by Yuansheng venture capital, and the old shareholder Zhang Ke Lingyi continued to make additional investment. This round of financing will be mainly used to promote the company's first protac pipeline for the treatment of autoimmune diseases to the stage of clinical research, as well as to develop follow-up projects and pipelines including tumors and other autoimmune diseases. Lingtai biology was founded in September 2019. Its R & D direction is to develop targeted protein degradation drugs, and focus on autoimmune, tumor and other disease fields. At present, Lingtai biology has developed a series of leading compounds with completely independent intellectual property rights based on its independently developed specific protein ubiquitination and degradation drug discovery platform (nano spud). Among them, the project with the fastest progress is the lt001 project for autoimmune diseases, which is expected to be submitted to ind by the end of 2022 and enter the clinical trial in 2023.